BioSpace News Archive

Acrobat Genomics, NanoString Technologies, Inc. (NASDAQ:NSTG), and the Illumina Accelerator announced today their collaboration with Stanford Medicine to discover new drug targets for gene editing-based therapeutics using GeoMx® Digital Spatial Profiling (DSP) technology.

BridgeBio Pharma, Inc. announced today that the updated six month results from Cohort 5 in PROPEL2, a Phase 2 trial of the investigational therapy, infigratinib in children with achondroplasia will be featured in an oral presentation at the Endocrine Society (ENDO) 2023 Annual Conference, taking place in Chicago.

Annovis Bio, Inc. announced that its PD phase III study of its lead compound buntanetap has reached full enrollment in a record nine months after it began.

QurAlis Corporation announced it will present new preclinical data showing the potential of the company’s antisense oligonucleotides generated from its proprietary FlexASO™ Splice Modulator Platform.

IMBdx Inc., a premier precision cancer diagnostic company accredited by CAP, announced today its plans to broaden its collaboration with AstraZeneca, a leading global biopharmaceutical company.

Techdow USA Announces Launch of its Generic Lovenox ® , (Enoxaparin Sodium – Preservative Free) in Prefilled Syringes.

Shineco, Inc., a provider of technologically advanced healthcare products and services, announced that in May 2023, its wholly owned subsidiary.

Hyperfine, Inc. is proud to be the first magnetic resonance imaging technology partner in an education-centric collaboration between the International Society for Magnetic Resonance in Medicine and the Bill & Melinda Gates Foundation.

Lantern Pharma Inc. (NASDAQ: LTRN) today announced it will be leveraging its AI platform, RADR®, in a research collaboration with Bielefeld University (Bielefeld, Germany) to develop antibody-drug conjugates (ADCs) with high therapeutic and antitumor potential.

Labcorp, a leading global life sciences company, announced that Fortrea Holdings Inc., a wholly owned subsidiary of Labcorp, has launched an offering of senior secured notes due 2030, subject to market conditions and other customary factors, in connection with the previously announced spinoff of Fortrea into a separate publicly traded company.